Esperion Therapeutics taken private by ARCHIMED in $1.1B deal
Esperion Therapeutics, a biopharmaceutical company, is being acquired by private equity firm ARCHIMED in a deal valued at $1.1 billion. Shareholders will receive $3.16 per share in cash at closing, representing a 58% premium over the stock's recent trading price. Additionally, they are eligible for contingent payments of up to $100 million tied to future milestones. The transaction is expected to close in the second half of 2025, subject to regulatory approvals and shareholder vote. ARCHIMED specializes in healthcare investments and plans to support Esperion's cholesterol-lowering drug portfolio, including its lead product Nexletol. The deal underscores continued private equity interest in the biotech sector.
Key facts
- Esperion Therapeutics is being taken private by ARCHIMED.
- The deal is valued at $1.1 billion.
- Shareholders receive $3.16 per share in cash at closing.
- The cash offer represents a 58% premium.
- Contingent payments of up to $100 million are included.
- Transaction expected to close in second half of 2025.
- ARCHIMED is a private equity firm focused on healthcare.
- Esperion's lead product is Nexletol for cholesterol.
Entities
Institutions
- Esperion Therapeutics
- ARCHIMED
Sources
- Quartz —